-+ 0.00%
-+ 0.00%
-+ 0.00%

*Vera Therapeutics On Track to Announce Primary Endpoint Results From the Atacicept Phase 3 ORIGIN Trial in IgA Nephropathy (IGAN) in 2Q

Dow Jones·05/06/2025 12:04:00

Please log in to view news